Comparative effects of Biophotonic therapies in viral and microbial illness

Author:

Abstract

The recently emerged coronavirus SARS-COV-2 viral strain that has caused COVID-19 illness is a member of the Coronaviridiae family, and is well known to produce respiratory, gastrointestinal and other illnesses in man and animals.1,2 Although the exact source or origin of the SARS-COV-2 viral strain has not yet been established, the coronavirus strain that causes Covid-19 is also genetically related to some zoonotic viruses isolated from pangolin, bats and camels, and which have previously caused respiratory illness in humans.3–5 Thus, the human infections likely could have occurred from an intermediate animal host via incidental interspecies transmission or other unconfirmed epidemiological origins as is believed to have occurred with the MERS strain. The Coronavirus Sars 2-Cov-19 pandemic first emerged in Wuhan, China on or before January 2020 and spread worldwide exponentially during the Spring to Fall of 2020.2 The newly described viral illness infected millions of people globally by year’s end and has continued into 2021 to the present, during which interval multiple infectious COVID-19 mutations have evolved, some with a more highly infectious potential than that of the initial virus. Continuing outbreaks of the viral mutants have emerged, often seemingly evading immunities formed from immunizations and earlier variants. Thus, the purpose of the present editorial review is to present an overview of the origins and progressive developments in the current coronavirus pandemic and to propose an application of biophotonic and bioelectromagnetic therapy as an often-effective adjunct in the treatment of potentially life threatening viral and microbial illnesses. This brief review paper concludes that biophotonic and bioelectromagnetic therapy (treatment) modalities have been utilized successfully for many years, prior to the development of antimicrobial and antiviral pharmaceutic agents as the current standard of care in common present-day therapies for infectious diseases

Publisher

MedCrave Group Kft.

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3